Can Test Reports Be Reused for Overseas Registration of Implantable Medical Devices?

Key Summary

Whether test reports can be reused for overseas registration of implantable medical devices depends on multiple factors. Companies should first determine whether the target country regulates the product as a medical device, then assess the risk class and registration pathway. In most cases, NMPA registration test reports, CE test reports, FDA 510(k) or PMA supporting data, and ISO 10993 biological evaluation reports can serve as the basis for core technical documentation—provided each report is checked against local requirements for test standards, batch numbers, laboratory qualifications, and report validity.

Reusable portions generally include objective data such as physical properties, chemical properties, biocompatibility, and animal tests. Data that often cannot be directly reused includes electrical safety standard differences, wireless coexistence, special labeling language, localization of clinical evaluation, and local ethical requirements. Companies also need to clarify the responsibilities of the local agent or authorized representative in report confirmation, certificate control, and post-market maintenance. Common risks include using outdated standards, having test laboratories not recognized by the target country, and reports failing to cover country-specific parameters—leading to deficiencies or retesting.

It is recommended that companies perform a gap analysis at project initiation before deciding whether to reuse, supplement, or retest, in order to reduce duplicate effort and review risks in multijurisdictional registrations.

Applicable Scenarios and Core Questions

Implantable products are medical devices introduced into the body through surgery and retained for more than 30 days, including orthopedic implants, cardiovascular implants, neurostimulators, artificial joints, and dental implants. For overseas registration, the reuse of test reports directly affects project timeline and budget.

A common situation: a company already holds an NMPA registration certificate or CE certificate and wishes to use the submitted test reports for registrations in GHWP member states, Southeast Asia, the Middle East, or Latin America. In this case, it is necessary to determine the role of those test reports in the original registration and the target country’s acceptance of the laboratory, standard version, and report content.

The core issue is not “copy and paste,” but rather “which evidence can be recognized by the target country’s regulatory authority, and which must be supplemented or redone.” This involves product classification, registration pathway, applicable standards, quality system, and clinical evaluation.

Registration Decision Logic

Step 1: Confirm whether the product falls within the target country’s medical device regulatory scope. Most countries regulate in vitro diagnostics separately from medical devices. Implantable products are typically classified as high or moderate risk, but the exact class may differ. For example, the same bone plate may be classified as Class D in one Southeast Asian country and Class C in another.

Step 2: Determine the product risk class and registration pathway. The risk class determines the documentation requirements, depth of review, and whether clinical data are required. Implantable products generally cannot be exempted from technical file review; some countries additionally require local clinical trials or local clinical data.

Step 3: Assess whether existing NMPA, CE, FDA, ISO 13485, MDSAP, or other market documentation can be reused. Focus on three aspects: whether the underlying test reports are based on the same product specification and materials, whether the test standards meet the target country’s requirements, and whether the testing laboratory is recognized by the target country.

Step 4: Confirm technical documentation, performance verification, risk management, clinical evaluation or clinical evidence, labeling and instructions, local agent, authorized representative, and post-market surveillance requirements. These items affect the degree of report reuse and the ongoing validity of certificates.

For multi-country registrations in GHWP member states, Southeast Asia, the Middle East, and Latin America, it is recommended to use a “core technical file plus local adaptation” approach: first establish a baseline file set containing biocompatibility, physical properties, chemical properties, product stability, risk management report, and a clinical evaluation summary, then adapt to each country’s specific requirements.

Documentation and Evidence

Reusable test reports typically include: mechanical performance test reports (e.g., tensile strength, fatigue testing, hardness, torque); chemical characterization and leachables reports; biological evaluation reports (e.g., ISO 10993 series); sterilization validation reports; shelf life and packaging validation reports; and certain product-specific animal study reports.

Data that cannot be directly reused includes: national-difference-based electrical safety reports (e.g., differences between GB 9706 and IEC 60601); radio certification for wireless modules; local language, units of measurement, and warning statements in labels and instructions; and clinical evaluation reports, especially those relying on local epidemiological data or local clinical practice.

For evidence chain management, companies should retain the original test protocol, sample batch number, test date, laboratory qualification, and raw data for each report. If reports are used for multiple country registrations, it is advisable to have the authorized representative or local agent review whether the report needs notarization, translation, or embassy/consulate legalization.

The validity period of test reports is also a key point. Some countries require that reports be issued no more than 2 or 3 years before the registration application. If a report is too old, additional stability data or retesting may be required. Additionally, if the product design, materials, or manufacturing process have changed, the original report may no longer be valid.

For high-risk implants, many countries require a clinical evaluation report or clinical evidence. In such cases, clinical data from other countries cannot simply be reused unless the target country accepts extrapolation from a homogeneous population. Companies should confirm in advance whether local clinical evaluation is required or whether equivalence arguments are acceptable.

Common Errors

• Error 1: Assuming that test reports referenced by a CE certificate are valid in all countries, while ignoring the target country’s requirements on test standard versions and laboratory qualifications.
• Error 2: Using the same biocompatibility report without verifying that it covers toxicological risk assessment requirements that are additional in the target country.
• Error 3: Ignoring model differences. If the original registration covers multiple models but the test report only covers one model, applying it to the target country may lead to inadequate scope.
• Error 4: Confusing clinical evaluation with clinical testing reports. A test report is a laboratory test; clinical evaluation is clinical evidence reasoning—they cannot substitute one another.
• Error 5: Failing to update labels and instructions, resulting in mismatch between the intended use and target population in the test report and the target country registration information.
• Error 6: Signing a local agent contract without clearly defining the obligation to review test reports and the responsibility for change notification, creating a risk to certificate control.

Company Preparation Checklist

• List the proposed target countries and confirm product classification and registration pathway for each.
• Inventory existing test reports, marking the test standard, issuing laboratory, date, and applicable models.
• Compare target country technical documentation requirements and create a gap analysis table clarifying which reports can be reused, which require supplementation, and which must be retested.
• Confirm whether the testing laboratory has ISO/IEC 17025 accreditation and whether it is accepted by the target country’s regulatory authority.
• Review the quality management system to ensure existing ISO 13485 or MDSAP certificates support multinational registration.
• Prepare localized versions of product labels, instructions, and packaging labeling, and verify consistency with the product description in test reports.
• Select a local agent or authorized representative and define its responsibilities for authenticity review of reports, change reporting, and post-market adverse event reporting.
• Establish a post-market surveillance plan, including implant registries, complaint handling, clinical follow-up, and periodic update reports.

AIMEILI Insights

The most common misjudgment companies make is thinking that “test reports are globally valid scientific documents.” From a regulatory perspective, test reports are both scientific data and administrative evidence. Target country reviewers look not only at the data itself, but also at whether the report conforms to local standard requirements, was issued by a recognized body, and is within its validity period.

The most important step early in a project is a gap analysis, not direct translation and notarization. It is recommended that companies spend 2–3 weeks to review target country requirements and produce a reusable report list and a supplemental testing list. This process significantly reduces the cost of later deficiency responses and repeat testing.

Which materials can be reused? Basic laboratory data such as material characterization, biocompatibility, physical and mechanical properties, sterilization validation, and packaging validation usually have high reuse value. What must be localized? Clinical evaluation reports, applicable standard differences, labeling and instructions, units of measurement, warning symbols, and certain countries’ radio or cybersecurity requirements.

Why are local agent, certificate control, change management, and renewal important? Because implantable products carry high post-market risk, regulatory authorities require the certificate holder to continuously update risk analysis and clinical evidence. If the local agent is not capable of handling test report updates, change notifications, and renewals, the original registration certificate may be suspended.

How can multinational registration reduce duplicate organization and deficiency risk? The core method is to establish a “master technical file library.” Companies should centrally archive all original reports, protocols, and raw data. When submitting to a new country, only local adaptation changes should be made. This avoids repeatedly requesting original records from testing laboratories and allows quick response to deficiency questions during review.

Common Follow-up Questions

Can the same biocompatibility report be used for all GHWP member state registrations?

Not necessarily. Although most GHWP member states adopt the ISO 10993 series, some countries require additional evaluation of leachables or additive toxicity, and others designate specific recognized laboratories. It is recommended to check the latest version of the target country’s standard list and confirm whether the issuing laboratory is on that country’s recognized list.

When using a CE report for Southeast Asian registration, is retesting required?

If the intended use, materials, design, and manufacturing process are completely identical, and the target country accepts IEC/ISO standards, retesting is usually not required. However, some countries require that test reports be issued by a locally recognized laboratory or undergo document review. If the report has exceeded its validity period or the product has undergone design changes, retesting is mandatory.

If the original registration report does not cover a new model, can model information be added to reuse the report?

No simple description can replace testing. When adding a new model, if the model difference does not affect key performance and safety indicators, a difference analysis report and the original test report can be submitted as supporting evidence. However, if the material, geometry, or surface treatment changes, corresponding mechanical, biological, or stability tests must be supplemented.